Questions About Cancer? 1-800-4-CANCER
News from NCI
  • Pre-B Acute Lymphoblastic Leukemia cell
    Trial results show high remission rate in leukemia following immune cell therapy
    NCI News Note

    (Posted: 10/12/2014) - Children and young adults (age 1 to age 30) with chemotherapy-resistant B-cell acute lymphoblastic leukemia (ALL) experienced high remission rates following treatment with an experimental immunotherapy. Results demonstrated that the immunotherapy treatment had anti-leukemia effects in patients and that the treatment was feasible and safe.

  • NCI scientists awarded National Medal of Technology and Innovation by President Obama
    NCI News Note

    (Posted: 10/07/2014) - President Obama announced that two NCI scientists would be recipients of the National Medal of Technology and Innovation -- the nation's highest honor for technological achievement. The honorees, John Schiller, Ph.D., Laboratory of Cellular Oncology (LCO), Center for Cancer Research, NCI, and Douglas Lowy, M.D., also from LCO and NCI deputy director, will receive their medals at a White House ceremony later in 2014.

  • A cell nucleus from a Hutchinson-Gilford Progeria Syndrome patient labelled with the nuclear protein lamina A (green).
    NCI scientists find protective mechanism against cancer in the cells of progeria patients
    NCI News Note

    (Posted: 10/02/2014) - NCI scientists have studied cells of patients with an extremely rare genetic disease that is characterized by drastic premature aging and discovered a new protective cellular mechanism against cancer. They found that cells from patients with Hutchinson Gilford Progeria Syndrome (HGPS), who typically do not develop cancer, contain a tumor protection mechanism that is mediated by BRD4.

  • NIH exceptional responders to cancer therapy study launched
    NCI Press Release

    (Posted: 09/24/2014) - The Exceptional Responders Initiative, a study to investigate the molecular factors of tumors associated with exceptional treatment responses of cancer patients to drug therapies, was launched today by NCI. Scientists will attempt to identify the molecular features of tumors that predict whether or not a particular drug or class of drugs will be beneficial.
    Questions & Answers View the article in Spanish

  • NCI’s Center for Global Health announces first major research grants to support portable technologies
    NCI News Note

    (Posted: 09/22/2014) - NCI’s Center for Global Health announced grants that will support the development and validation of low-cost, portable technologies. These technologies have the potential to improve early detection, diagnosis, and non-invasive or minimally invasive treatment of several cancer types that have a particularly high prevalence in a number of low- and middle-income countries.
    View the article in Spanish

  • Microarray chips used in genome-wide association studies
    New genetic risk variants identified in multiethnic analysis of prostate cancer
    NCI News Note

    (Posted: 09/14/2014) - Researchers have newly identified 23 common genetic variants -- one-letter changes in DNA known as single-nucleotide polymorphisms or SNPs -- that are associated with risk of prostate cancer. These results come from an analysis of more than 10 million SNPs in data pooled from studies that included over 43,000 men with prostate cancer and nearly 44,000 men without the disease. Study participants were from Australia, Ghana, Japan, the United Kingdom, and the United States and were of diverse ancestry.

  • A black and white line drawing of a fallopian tube, which looks like an elongated trumpet flower
    NCI study examines outcomes from surgery to prevent ovarian cancer
    NCI News Note

    (Posted: 09/08/2014) - A new study looked at women at high risk of ovarian cancer who had no clinical signs of the disease and who underwent risk-reducing salpingo-oophorectomy (RRSO). The study results showed cancer in the removed tissues of 2.6 percent (25 of 966) of the participants.

  • Risk factors identified for certain lymphoma subtypes
    NCI News Note

    (Posted: 09/02/2014) - In a large international collaborative analysis of risk factors for non-Hodgkin lymphoma (NHL), scientists were able to quantify risk associated with medical history, lifestyle factors, family history of blood or lymph-borne cancers, and occupation for 11 different NHL subtypes, including less common subtypes.

  • Credit:Sang Eun Lee (Samsung Medical Center).  Illustration shows chromophobe renal cell carcinoma (a rare type of kidney tumor) highlighting important roles for mtDNA mutations and structural alterations involving TERT promoters as white dots on a purple background
    Rare kidney tumor provides insights on role of metabolic changes in cancer
    NCI News Note

    (Posted: 08/21/2014) - Researchers in The Cancer Genome Atlas (TCGA) Network have uncovered a number of new findings about the biology and development of a rare form of kidney cancer. They found that the disease – chromophobe renal cell carcinoma – stems in part from alterations in genes in the mitochondria, the cell’s energy supplier.

  • NIH announces the launch of 3 integrated precision medicine trials; ALCHEMIST is for patients with certain types of early-stage lung cancer
    NCI Press Release

    (Posted: 08/18/2014) - The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, will identify early-stage lung cancer patients with tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those changes can lead to improved survival.
    Questions & Answers View the article in Spanish

1 2 3 4 5 6 7 8 9 10  Next >